Abstract | INTRODUCTION: MATERIALS AND METHODS: An open randomized comparative longitudinal study was conducted on 40 moderate degree COPD patients over a period of one year. The patients were randomized into Group-1:receiving Acebrophylline 100mg twice daily and Group-2: receiving sustained release (SR) Theophylline 300mg once daily orally, in addition to 18μgm Tiotropium inhalation per day through metered dose inhaler. Spirometric variables, symptomatic benefit and adverse effects were recorded on three visits (day '0', '21' and '42'). All the data were analyzed by SPSS version 17. RESULTS: A comparable clinical improvement of symptoms score and spirometric parameters with both the drugs has been observed (p-value>0.05). Amount of sputum, frequency of use of reliever medication and dyspnoea showed improvement with both the drugs but cardiovascular side effects are less with Acebrophylline. CONCLUSION: This study reaffirms the rationale of use of Methylxanthines as add on therapy with LAMA in COPD management and cardiac safety level with Acebrophylline was considerable.
|
Authors | Sumit Roy Tapadar, Maumita Das, Arunabha Datta Chaudhuri, Santanu Basak, Anil Baran Singha Mahapatra |
Journal | Journal of clinical and diagnostic research : JCDR
(J Clin Diagn Res)
Vol. 8
Issue 9
Pg. MC11-4
(Sep 2014)
ISSN: 2249-782X [Print] India |
PMID | 25386474
(Publication Type: Journal Article)
|